

Committed to Delivering Affordable Proton Cancer Therapy

Energy Focused on Saving Lives Figure 1. The second of th

Forward Looking Statement



This presentation may contain certain projections and other forward-looking statements with respect to the financial condition, results of operations, businesses and prospects of **Advanced Oncotherapy plc** ("**AVO**", "**Advanced Oncotherapy**" or the "**Company**"). These statements are based on current expectations and involve risk and uncertainty because they relate to events and depend upon circumstances that may or may not occur in the future. There are a number of factors which could cause actual results or developments to differ materially from those expressed or implied by these forward-looking statements. Any of the assumptions underlying these forward-looking statements could prove inaccurate or incorrect and therefore any results contemplated in the forward-looking statements may not actually be achieved.

Nothing contained in this presentation should be construed as a profit forecast or profit estimate. Investors or other recipients are cautioned not to place undue reliance on any forward-looking statements contained herein. Advanced Oncotherapy undertakes no obligation to update or revise (publicly or otherwise) any forward-looking statement, whether as a result of new information, future events or other circumstances. Neither this presentation nor any verbal communication shall constitute an invitation or inducement to any person to subscribe for or otherwise acquire securities in Advanced Oncotherapy.

Advanced Oncotherapy – Who Are We?



AIM listed Company

- \$150m
- Londor
- 50 People
- UK, Switzerland, US



CERN Spin-off

LHC (Large Hadron Collider)



27 km

14,000,000 Me\

99.9999% speed of light

 LIBO (LINAC BOoster), evidence of linear proton acceleration

Progress so far



- Validated ground-breaking technology in proton therapy
- First patients by the end of 2017
- Leading component suppliers to achieve main products
- 3 signed purchase orders and large pipeline
 - Harley street
 - Huai'an city
 - Changchun city
 - Syracuse (Letter of exclusivity)
 - 4 framework agreements in China


X-rays, a Key Modality… Now at Its Physical Limits



21m new cases


50% survival

\$286 billion cost






Bragg peak effect



- Since 1954
- 120,000 + patients
- Children
- Hard to treat tumours
- Only 54 centres (or c. 120 treatment rooms)





Implications to Current Issues



- Only 54 centres in the world
- No facilities in the UK
- 150 patients sent outside UK every year
- Treatment costs in excess of £100k
- Focus on "lucrative" indications
- Facilities open 24 hours a day
- Push back from payors

What Do New Systems Need to Have?



- Cost effective
 - Equipment
 - Building cost
 - Running cost
- More flexible
- More precise and dynamic
- More integrated, turn-key

Video – Pebble Mill Proton Therapy Centre





Competitors

AVO

 $\sqrt{\sqrt{}}$

$$\checkmark$$

$$\checkmark$$







Unique Execution Capabilities



- Proton therapy, nothing new
- Our technology = already validated



LIBO (Linac Booster

Our team

- Dr Mike Sinclair
- Sanjeev Pandya
- Nicolas Serandour
- Prof Steve Myers
- Bob Rose
- Donatella Ungaro
- Prof Hanne Kooy
- Prof Ugo Amaldi
- Dr Nick Plowman
- Prof Jay Loeffler
- Dr Margaret Spittle
- Lord David Evans
- Michael Bradfield
- Tim Lebus
- Dr Henri Vanni
- Dr Euan Thomson
- Prof Chris Nutting
- Dr Sanjeev Kanoria

Our partners



SIEMENS

Our Goals



120 treatment rooms vs 13,000 rooms

 Below long-term NHS guidance set at £35k for the cost of treating cancer

Make treatment accessible